12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersProtara Therapeutics (NASDAQ:TARA) stock increased by 40.3% to $5.64 during Friday's pre-market session. The market value of their outstanding shares is at $64.4 million. Candel Therapeutics (N
GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine
GeoVax Labs, Inc. (Nasdaq: GOVX) today announced that its Chief Scientific Officer, Mark Newman, PhD, presented data on GEO-CM04S1, the Company's next-generation Covid-19 vaccine candidate, during the 24th Annual World Vaccine Congress in Washington, DC.
GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress
ATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious di
GeoVax to Present at the 36th Annual Roth Conference
ATLANTA, GA, March 12, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious d
Noble Financial Reaffirms Their Buy Rating on GeoVax Labs (GOVX)
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
Manufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines ATLANTA, GA, March 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasda
GeoVax Labs Files $100M Mixed Securities Shelf
Earnings Call Summary | GeoVax Labs(GOVX.US) Q4 2023 Earnings Conference
The following is a summary of the GeoVax Labs, Inc. (GOVX) Q4 2023 Earnings Call Transcript:Financial Performance:GeoVax Labs reported a net loss for 2023 of $265 million, or $14.29 per share, driven
Analysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX), Madrigal Pharmaceuticals (MDGL) and Spyre Therapeutics (SYRE)
GeoVax GAAP EPS of -$14.29 Beats by $0.26
Geovax Labs Q4 2023 GAAP EPS $(3.940) Misses $(2.780) Estimate
Geovax Labs (NASDAQ:GOVX) reported quarterly losses of $(3.940) per share which missed the analyst consensus estimate of $(2.780) by 41.73 percent.
GeoVax Labs Anticipates Reporting Additional Results From the Gedeptin Phase 1/2 Clinical Trial in 1H 2024>GOVX
GeoVax Labs Anticipates Reporting Additional Results From the Gedeptin Phase 1/2 Clinical Trial in 1H 2024>GOVX
Press Release: GeoVax Reports 2023 Year-End Financial Results and Provides Business Update
GeoVax Reports 2023 Year-End Financial Results and Provides Business Update Progress across the pipeline in multiple clinical trials, including Phase 2 program of GEO-CM04S1, next-generation Covid-1
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. • NB Bancorp (NASDAQ:NBBK) is likely to report ear
Earnings Outlook For Geovax Labs
Geovax Labs (NASDAQ:GOVX) is set to give its latest quarterly earnings report on Thursday, 2024-02-29. Here's what investors need to know before the announcement.
InMed Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
The Dow Jones index closed higher by over 450 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders
GeoVax Labs(GOVX.US) Officer Buys US$19,781.16 in Common Stocks
$GeoVax Labs(GOVX.US)$ Officer DODD DAVID A purchased 8,729 shares of Common Stocks on Feb 21, 22, 2024 at an average price of $2.2661 for a total value of $19,781.16.Source: Announcement What is stat
Press Release: GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024
GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire
GeoVax to Present at the 2024 BIO CEO & Investor Conference
GeoVax senior management will also conduct one-on-one meetings during the conference. For more information or to schedule a meeting, please visit the conference page here or contact GeoVax Investor Relations.
GeoVax Labs Avoids Nasdaq Delisting With Reverse Stock Split
No Data